relapsing remitting multiple sclerosis

Summary

Summary: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Top Publications

  1. ncbi European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Gla
    G Comi
    Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy
    Ann Neurol 49:290-7. 2001
  2. ncbi Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis
    B Audoin
    NMR Research Unit, Institute of Neurology, University College London, London, UK
    Mult Scler 13:483-9. 2007
  3. ncbi Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study
    Jens Wuerfel
    Institute of Neuroimmunology, Charite, Berlin, Germany
    Brain 127:111-9. 2004
  4. ncbi Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis
    Jürgen Haas
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany
    Eur J Immunol 35:3343-52. 2005
  5. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
  6. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
  7. doi Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
    L K Fisniku
    NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Brain 131:808-17. 2008
  8. ncbi Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Italy
    Neurology 57:1239-47. 2001
  9. ncbi Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
    Annette Langer-Gould
    Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:375-81. 2005
  10. ncbi Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis
    Mikael Schwarz
    Glycominds Ltd, Lod 71291, Israel
    J Neurol Sci 244:59-68. 2006

Detail Information

Publications248 found, 100 shown here

  1. ncbi European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Gla
    G Comi
    Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy
    Ann Neurol 49:290-7. 2001
    ..randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS)...
  2. ncbi Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis
    B Audoin
    NMR Research Unit, Institute of Neurology, University College London, London, UK
    Mult Scler 13:483-9. 2007
    ....
  3. ncbi Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study
    Jens Wuerfel
    Institute of Neuroimmunology, Charite, Berlin, Germany
    Brain 127:111-9. 2004
    ..Our data indicate that inflammation is accompanied by altered local perfusion, which can be detected prior to permeability of the BBB...
  4. ncbi Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis
    Jürgen Haas
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany
    Eur J Immunol 35:3343-52. 2005
    ..The effect was persistent and not due to responder cell resistance or altered survival of Treg, suggesting that a defective immunoregulation of peripheral T cells mediated by (CD4+)CD25high T lymphocytes promotes CNS autoimmunity in MS...
  5. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
    ..The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression...
  6. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
    ..Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS...
  7. doi Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
    L K Fisniku
    NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Brain 131:808-17. 2008
    ..001). The estimated rate of lesion growth over 20 years was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2...
  8. ncbi Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Italy
    Neurology 57:1239-47. 2001
    ..Furthermore, there are no data on the impact of IVMP on T1 black holes or whole-brain atrophy...
  9. ncbi Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
    Annette Langer-Gould
    Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:375-81. 2005
    ..The patient was treated with systemic cytarabine, and two months later, his condition had improved...
  10. ncbi Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis
    Mikael Schwarz
    Glycominds Ltd, Lod 71291, Israel
    J Neurol Sci 244:59-68. 2006
    ..0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management...
  11. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
    ..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
  12. ncbi Secondary progressive multiple sclerosis: current knowledge and future challenges
    Marco Rovaris
    Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Lancet Neurol 5:343-54. 2006
    ....
  13. doi Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study
    Laura Mendozzi
    Multiple Sclerosis Rehabilitation Unit, Milan, Italy
    Mult Scler 16:238-47. 2010
    ..Poor sleep is common in MS and it contributes to fatigue. The beta interferons produce systemic effects which may not adapt and may induce fatigue...
  14. pmc The relation between inflammation and neurodegeneration in multiple sclerosis brains
    Josa M Frischer
    Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
    Brain 132:1175-89. 2009
    ..It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease...
  15. ncbi Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods
    Valerie M Anderson
    MS NMR Research Unit, University College London, Institute of Neurology, Queen Square, London, UK
    J Neuroimaging 17:61-8. 2007
    ....
  16. ncbi Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review
    Annette Langer-Gould
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
    Arch Neurol 63:1686-91. 2006
    ..To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis...
  17. pmc Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level
    Koen Venken
    Hasselt University, Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium
    Immunology 123:79-89. 2008
    ..Our results also suggest that Tregs accumulate in the CSF of RR-MS patients, in an attempt to down-regulate local inflammation in the central nervous system...
  18. ncbi Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine
    H Bartosik-Psujek
    Department of Neurology, Medical University, Lublin, Poland
    Acta Neurol Scand 109:390-2. 2004
    ..The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines--interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted)...
  19. ncbi A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  20. ncbi Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
    B K Kleinschmidt-Demasters
    Department of Pathology, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 353:369-74. 2005
    ..There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization...
  21. ncbi Oral fingolimod (FTY720) for relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, Basel, Switzerland
    N Engl J Med 355:1124-40. 2006
    ..Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis...
  22. doi A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    Gavin Giovannoni
    Queen Mary University London, the Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    N Engl J Med 362:416-26. 2010
    ..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis...
  23. ncbi Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
    K P Johnson
    Maryland Center for MS, Baltimore, MD 21201, USA
    Acta Neurol Scand 111:42-7. 2005
    ..To assess the long-term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing-remitting multiple sclerosis (RRMS)...
  24. pmc Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis
    Laure Michel
    INSERM U643, CHU Nantes, Institut de Transplantation et de Recherche en Transplantation ITERT, and Faculté de Médecine, Universite de Nantes, Nantes, France
    J Clin Invest 118:3411-9. 2008
    ..The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS...
  25. ncbi Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  26. doi 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    Paul O'Connor
    St Michael s Hospital, Toronto, Canada
    Lancet Neurol 8:889-97. 2009
    ....
  27. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    ..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  28. ncbi Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis
    Maja Eriksson
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden
    Mult Scler 9:260-74. 2003
    ..Predictors from this study could be used to refine historically controlled trials...
  29. ncbi Cortical demyelination and diffuse white matter injury in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 128:2705-12. 2005
    ..With chronicity, diffuse inflammation accumulates throughout the whole brain, and is associated with slowly progressive axonal injury in the NAWM and cortical demyelination...
  30. doi Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a
    Peter Joseph Jongen
    MS4 Research Institute, Ubbergseweg 34, 6522 KJ, Nijmegen, The Netherlands
    J Neurol 257:584-9. 2010
    In patients with relapsing remitting multiple sclerosis (RRMS), the effect of interferon-beta (INFb) on health-related quality of life (HR-QoL) is not firmly documented...
  31. ncbi Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis
    Marien Gadea
    Area de Psicobiologia, Facultat de Psicologia, Universitat de Valencia, Avda Blasco Ibáñez 21, E 46010, Valencia, Spain
    Brain 127:89-98. 2004
    ..The use of both 1H-MRS and DL showed the connection between axonal damage at right locus coeruleus and auditive selective attention dysfunction in early-stage RRMS...
  32. ncbi [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients]
    E Le Page
    Service de Neurologie, Hopital Pontchaillou, Rennes
    Rev Neurol (Paris) 162:185-94. 2006
    ..We report an observational study of 100 aggressive relapsing remitting (RR) MS patients treated by induction therapy with MITOX and followed up to 5 years...
  33. ncbi Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results
    Rana Karabudak
    Hacettepe University, Faculty of Medicine, Department of Neurology, Neuroimmunology Unit, 06100 Ankara, Turkey
    J Neurol 251:279-83. 2004
    ..The MMP-9 levels showed no significant changes while TIMP-1 levels gradually and significantly increased during 3rd and 6th months of therapy compared with pretreatment levels...
  34. doi Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis
    J Smolders
    School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
    Mult Scler 14:1220-4. 2008
    ..We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate...
  35. ncbi Natural history of multiple sclerosis: a unifying concept
    Christian Confavreux
    Service de Neurologie A, the European Database for Multiple Sclerosis EDMUS Coordinating Center and INSERM U 433, Hopital Neurologique, Lyon, France
    Brain 129:606-16. 2006
    ....
  36. ncbi Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study
    P Kapeller
    NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    J Neurol 248:131-8. 2001
    ..This preliminary finding should be confirmed in a larger cohort, and follow-up studies are also needed to determine the prognostic and pathophysiological significance of these early changes...
  37. ncbi Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis
    Laura Airas
    Department of Neurology and MediCity Research Laboratory, University of Turku, PO Box 52, 20521Turku, Finland
    J Neuroimmunol 177:132-5. 2006
    ..388+/-102 ng/ml, p=0.0068). We propose that VAP-1 might participate in controlling leukocyte entry into inflamed brain...
  38. ncbi A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis
    Derek Soon
    Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom
    J Neurol 254:306-14. 2007
    ..12). There is evidence of a subtle BBB leakage within visibly non-enhancing lesions in RRMS that was not modified by alpha4 integrin blockade in this substudy cohort...
  39. doi Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison
    Mark S Freedman
    Department of Medicine Neurology, University of Ottawa, Ottawa, Ontario, Canada
    Eur Neurol 60:1-11. 2008
    ..In the absence of head-to-head studies for all products used to treat RRMS, it still may be possible to compare treatment effects by applying evidence-based medicine principles...
  40. pmc Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis
    M Bieniek
    NMR Research Unit, Institute of Neurology, University College London, London, UK
    J Neurol Neurosurg Psychiatry 77:1036-9. 2006
    ..An improved understanding of the causes of early progressive disability in primary progressive multiple sclerosis (PPMS) could provide mechanistic targets for therapeutic intervention...
  41. ncbi Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
    E L J Hoogervorst
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 8:415-9. 2002
    ..Multiple sderosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients...
  42. ncbi Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials
    M Chofflon
    Policlinique de Neurologie, Hopital Cantonal Universitaire, Genève Switzerland
    Eur J Neurol 7:369-80. 2000
    ..Furthermore, as inflammatory brain lesions in MS have been shown to exhibit more extensive and early axonal damage than previously suspected, early treatment may be advisable in order to delay disease progression in RRMS...
  43. doi Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
    Daniel D Mikol
    University of Michigan Medical Center, Ann Arbor, MI 48109 0316, USA
    Lancet Neurol 7:903-14. 2008
    ..Our aim in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients with RRMS...
  44. ncbi Natalizumab for multiple sclerosis
    Richard M Ransohoff
    Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, OH 44195, USA
    N Engl J Med 356:2622-9. 2007
  45. ncbi Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis
    R M Valenzuela
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Mult Scler 13:754-62. 2007
    ..To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-gamma and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS)...
  46. ncbi Cytokine mRNA expression in patients with multiple sclerosis and fatigue
    Peter Flachenecker
    Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Mult Scler 10:165-9. 2004
    ..Fatigue is one of the most common disabling symptoms in patients with multiple sclerosis (MS), but the putative role of proinflammatory cytokines remains to be elucidated...
  47. ncbi Clinical characteristics of responders to interferon therapy for relapsing MS
    E Waubant
    UCSF MS Center, San Francisco, CA 94117, USA
    Neurology 61:184-9. 2003
    ..To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders...
  48. ncbi Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis
    Andreas Hug
    Department of Neurology, University of Heidelberg, Heidelberg, Germany
    J Immunol 171:432-7. 2003
    ..Altogether, our findings suggest that an impaired thymic export function and, as a consequence, altered ability to maintain T cell homeostasis and immune tolerance may play an important pathogenic role in RRMS...
  49. doi Immunomodulatory effects of Vitamin D in multiple sclerosis
    Jorge Correale
    Raul Carrea Institute for Neurological Research, FLENI, Montaneses 2325, 1428 Buenos Aires, Argentina
    Brain 132:1146-60. 2009
    ..and thirty-two Hispanic patients with clinically definite multiple sclerosis were studied, 58 with relapsing remitting multiple sclerosis during remission, 34 during relapse and 40 primary progressive multiple sclerosis cases...
  50. doi A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
    Claudia C Kaiser
    Department of Anesthesiology, University of Illinois, Chicago, 60612, United States
    J Neuroimmunol 211:124-30. 2009
    ..These results show that pioglitazone was well tolerated in RRMS patients with indications of beneficial effects, warranting further trials to establish clinical efficacy...
  51. ncbi Evidence of early cortical atrophy in MS: relevance to white matter changes and disability
    N De Stefano
    Institute of Neurological Sciences, University of Siena, Italy
    Neurology 60:1157-62. 2003
    ....
  52. ncbi Oral simvastatin treatment in relapsing-remitting multiple sclerosis
    Timothy Vollmer
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ, USA
    Lancet 363:1607-8. 2004
    ..0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability...
  53. ncbi Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease
    J Killestein
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 7:145-50. 2001
    ....
  54. doi Abnormal sensorimotor control, but intact force field adaptation, in multiple sclerosis subjects with no clinical disability
    Maura Casadio
    Department of Informatics, Systems and Telematics and Research Centre for Neuroscience and Neuroengineering, University of Genoa, Via Opera Pia 13, Genoa 16145, Italy
    Mult Scler 14:330-42. 2008
    ..This indicates that early in the disease MS subjects have intact adaptive capabilities, but impaired movement execution...
  55. pmc Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis
    Yulin Ge
    Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, 650 First Ave, Room 615, New York, NY 10016, USA
    Arch Neurol 65:812-6. 2008
    ..Ultrahigh-field (eg, 7-T) magnetic resonance imaging (MRI) has become a tool for assessing vascular involvement in MS lesions owing to markedly increased image resolution and susceptibility contrast of venous blood...
  56. ncbi Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression
    Koen Venken
    Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Hasselt University, Diepenbeek, Belgium
    J Neurosci Res 83:1432-46. 2006
    ..These data are the first to demonstrate differences in function and FOXP3 expression of CD4(+)CD25(+) T cells from patients with RR- and SP-MS...
  57. ncbi Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
    Darcy Cox
    University of California, San Francisco, USA
    J Neurosci Nurs 38:167-71. 2006
    ..Nurses who are familiar with these tools have the opportunity to have a significant positive impact on patient comfort, confidence, and, ultimately, successful long-term adherence to disease-modifying medications...
  58. pmc The effect of immunomodulatory treatment on multiple sclerosis fatigue
    L M Metz
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Neurol Neurosurg Psychiatry 75:1045-7. 2004
    ..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...
  59. ncbi Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis
    D T Chard
    NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    Brain 125:2342-52. 2002
    ..The correlation of clinical impairment with a raised NAWM Ins may indicate that glial proliferation also relates to function at this stage of the disease...
  60. ncbi Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis
    Gordon Francis
    Expert Opin Drug Saf 3:289-303. 2004
    ..The potential advantages of IFN-beta therapy may be enhanced by regular monitoring of efficacy and safety in order to maintain patients on therapy beyond the first few months when side effects are most apparent...
  61. pmc Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
    ..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
  62. ncbi Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study
    A Prinster
    Biostructure and Bioimaging Institute, National Council for Research, Edificio 10, Via Pansini, 5, 80131 Napoli, Italy
    Neuroimage 29:859-67. 2006
    ..Our findings suggest that in RR-MS cortical GM reduction preferentially involves left fronto-temporal structures and deep GM, the latter correlating preferentially to global lesion load...
  63. ncbi A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    P W O'Connor
    University of Toronto, Ontario, Canada
    Neurology 66:894-900. 2006
    ..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses...
  64. ncbi Brain atrophy in clinically early relapsing-remitting multiple sclerosis
    D T Chard
    NMR Research Unit, Department of Clinical Neurology, Institute of Neurology, University College London, UK
    Brain 125:327-37. 2002
    ..The lack of correlation between lesion load measures and WMF suggests that pathological changes in white matter may occur by mechanisms which are at least partly independent from overt lesion genesis in early multiple sclerosis...
  65. ncbi Defining interferon beta response status in multiple sclerosis patients
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 56:548-55. 2004
    ..MRI classification may facilitate rational therapeutic decisions, better clinical trial designs, and studies correlating biomarkers with therapeutic response...
  66. pmc Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis
    Friedemann Paul
    Cecilie Vogt Clinic for Neurology in the HELIOS Clinic Berlin Buch, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany
    PLoS ONE 3:e1928. 2008
    ..Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS...
  67. doi Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis
    Jack C Sipe
    Associate Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Expert Rev Neurother 10:365-75. 2010
    ..Assessments and conclusions will include a speculative 5-year outlook...
  68. ncbi Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions
    L W Whitney
    Molecular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, NIH, Bldg. 10/Rm 5B-16, Bethesda, MD 20892-1400, USA
    J Neuroimmunol 121:40-8. 2001
    ..Although these findings are not specific for MS, they identify a potentially important component of pro-inflammatory activity in the demyelinating process in MS and suggest a possible target for anti-inflammatory therapy in MS...
  69. doi Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Ludwig Kappos
    University Hospital Basel, Basel, Switzerland
    Lancet 372:1463-72. 2008
    ..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
  70. pmc Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis
    M S A Deloire
    EA 2966 Neurobiology of Myelin Disorders Laboratory, University Victor Segalen, Case 78, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    J Neurol Neurosurg Psychiatry 76:519-26. 2005
    ....
  71. ncbi Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    C Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Neurology 64:987-91. 2005
    ..The purpose of this study was to evaluate safety, tolerability, and efficacy on MRI lesions of two different doses of laquinimod compared with placebo in patients with relapsing MS...
  72. doi Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment
    G Koch
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita Tor Vergata, Rome, Italy
    Mult Scler 14:995-8. 2008
    ..rTMS of the motor cortex may be a useful approach to treat cerebellar impairment in MS patients...
  73. pmc Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study
    W Rashid
    MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
    J Neurol Neurosurg Psychiatry 77:51-5. 2006
    ..It is less clear how early it can be detected in relapsing-remitting (RR) MS, and whether early cord atrophy relates to the concurrent or future clinical course...
  74. ncbi Optimizing the association between disability and biological markers in MS
    N F Kalkers
    MS MRI Center, VU Medical Center, Amsterdam, The Netherlands
    Neurology 57:1253-8. 2001
    ..The authors studied the relation of brain volume measurements with the MS Functional Composite (MSFC) in an attempt to improve the clinico-radiologic association...
  75. pmc A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Trieste, Italy
    J Neurol Neurosurg Psychiatry 70:773-80. 2001
    ....
  76. ncbi A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
    C C Ford
    MIND Imaging Center, Albuquerque, NM, USA
    Mult Scler 12:309-20. 2006
    A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study, and the neurological status of 'Withdrawn' patients was assessed at a 10-year ..
  77. ncbi Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
    Jason Ramtahal
    The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK
    J Neurol 253:1160-4. 2006
    ..Acetate appears a safe and effective option for continuing disease modification in patients with relapsing remitting multiple sclerosis treated with Mitoxantrone...
  78. ncbi Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Per Soelberg Sorensen
    Department of Neurology, Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark
    Lancet 362:1184-91. 2003
    ..We aimed to assess the clinical effect of neutralising antibodies...
  79. ncbi Emerging oral therapies for multiple sclerosis
    B A Cohen
    Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Clin Pract 61:1922-30. 2007
    ..Therefore, alternative MS treatments with less invasive routes of administration and new modes of action are needed to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efficacy...
  80. ncbi Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality
    Letizia Leocani
    Department of Neurology, Clinical Neurophysiology and Neurorehabilitation, University Vita Salute, Scientific Institute Hospital San Raffaele, Milan, Italy
    Neurorehabil Neural Repair 21:273-8. 2007
    ..The objective of this study was to investigate the usefulness of VR in the assessment of short-term motor learning in multiple sclerosis (MS)...
  81. ncbi Longitudinal follow-up of "benign" multiple sclerosis at 20 years
    Ana Luiza Sayao
    Department of Medicine Neurology, University of British Columbia, Vancouver, BC, Canada
    Neurology 68:496-500. 2007
    ..To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset...
  82. ncbi Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates
    Valerie M Anderson
    MS NMR Research Unit, University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 254:1588-94. 2007
    ....
  83. ncbi Genomic effects of IFN-beta in multiple sclerosis patients
    Bianca Weinstock-Guttman
    Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, NY 14203, USA
    J Immunol 171:2694-702. 2003
    ..The findings demonstrate that IFN-beta treatment induces specific and time-dependent changes in multiple mRNAs in lymphocytes of multiple sclerosis patients that could provide a framework for rapid monitoring of the response to therapy...
  84. ncbi Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor
    Tjalf Ziemssen
    Department of Neuroimmunology, Max Planck Institute of Neurobiology, Martinsried, Germany
    Brain 125:2381-91. 2002
    ..The different assays and different TCLs yielded similar, consistent results. All four GA-specific T-cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF...
  85. ncbi A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study
    J M Morales-Gonzáles
    Department of Research, Ministry of Labour and Social Affairs, Madrid, Spain
    Mult Scler 10:47-54. 2004
    ..To describe a holistic and comprehensive approach to the assessment of sufferer's perceptions of health-related quality of life (HRQoL) in a cohort of multiple sclerosis (MS) patients...
  86. ncbi The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis
    L Julian
    University of California, San Francisco, CA, USA
    Mult Scler 13:81-6. 2007
    ..Furthermore, patients may be more accurate reporters of their cognitive impairment after successful treatment for depression, suggesting that depression decreases the accuracy of patient reported cognitive impairment...
  87. ncbi Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy
    Enrico Fainardi
    Multiple Sclerosis Center, Department of Neurology, University of Ferrara, Arcispedale S Anna, Corso della Giovecca 203, Ferrara I 44100, Italy
    J Neuroimmunol 148:206-11. 2004
    ....
  88. ncbi Statins as immunomodulators: comparison with interferon-beta 1b in MS
    O Neuhaus
    Department of Neurology, Multiple Sclerosis Research Group, Karl Franzens Universität, Graz, Austria
    Neurology 59:990-7. 2002
    ..In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b...
  89. ncbi Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA
    Ann Neurol 60:236-42. 2006
    ..To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS)...
  90. ncbi Predictors of relapse rate in MS clinical trials
    U Held
    Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany
    Neurology 65:1769-73. 2005
    ..The aim of this study was to determine the relative contribution of different possible prognostic factors available at baseline to the on-study relapse rate in MS...
  91. ncbi In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study
    F Agosta
    Neuroimaging Research Unit, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Brain 130:2211-9. 2007
    ..MS cord pathology also seems to be independent of concomitant brain changes, to develop at different rates according to disease phenotype, and to be associated to medium-term disability accrual...
  92. ncbi Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
    O Lily
    Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Mult Scler 12:808-13. 2006
    ..In this study, the LMSQoL scale was responsive to change and was easy to administer in a clinical setting...
  93. ncbi The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy
    M Trojano
    Department of Neurological and Psychiatric Sciences, University of Bari, Piazza Giulio Cesare 11, I 70124, Bari, Italy
    Neurol Sci 26:S179-82. 2005
    ..05) increase of EDSS was observed in all treatment groups from baseline to 48 months, followed thereafter by a plateau. The IFNbeta-1b group showed more withdrawals (19%) compared with Avonex (6%) and Rebif (7%) at 6 years...
  94. ncbi A randomized crossover study of bee sting therapy for multiple sclerosis
    T Wesselius
    Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands
    Neurology 65:1764-8. 2005
    ..Bee sting therapy is increasingly used to treat patients with multiple sclerosis (MS) in the belief that it can stabilize or ameliorate the disease. However, there are no clinical studies to justify its use...
  95. ncbi Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status
    Martin Masek
    Department of Radiology, General Teaching Hospital, Prague, Czech Republic
    Neuro Endocrinol Lett 29:461-6. 2008
    ..To compare a time line of brain atrophy in patients with SPMS, patients with relapsing-remitting multiple sclerosis (RRMS) and the healthy population...
  96. ncbi Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
    A Minneboo
    MS Center of the VU University Medical Center, Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:917-23. 2008
    ..The aim of this study was to investigate whether adding MRI parameters to a model with only clinical parameters could improve these associations...
  97. doi Gray matter atrophy is related to long-term disability in multiple sclerosis
    Leonora K Fisniku
    Nuclear Magnetic Resonance Research Unit, Institute of Neurology, University College London, UK
    Ann Neurol 64:247-54. 2008
    ..To determine the relation of gray matter (GM) and white matter (WM) brain volumes, and WM lesion load, with clinical outcomes 20 years after first presentation with clinically isolated syndrome suggestive of multiple sclerosis (MS)...
  98. doi Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
    ....
  99. ncbi Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS)
    M H Gottesman
    Winthrop University Hospital, Old Country Road, Mineola, NY 11501, USA
    Mult Scler 12:271-80. 2006
    ..The 500-microg dose of interferon beta-1b was well tolerated in the short-term with escalation and premedication in these patients, most of whom had previously been receiving 250 microg interferon beta-1b...
  100. ncbi Diagnosis and management of multiple sclerosis: case studies
    Douglas A Woo
    Multiple Sclerosis Program, Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9036, USA
    Neurol Clin 24:199-214. 2006
    ....
  101. pmc Longitudinal course of depression symptoms in multiple sclerosis
    P A Arnett
    Penn State University, Psychology Department, 522 Bruce V Moore Bldg, University Park, PA 16802 3105, USA
    J Neurol Neurosurg Psychiatry 77:606-10. 2006
    ..Despite the high lifetime prevalence of depression in multiple sclerosis (MS), its longitudinal course is poorly understood...

Research Grants107 found, 100 shown here

  1. Characterization of Symptom Occurrence in Persons with Multiple Sclerosis
    Pamela K Newland; Fiscal Year: 2010
    ..This proposal provides new insight into the complexity of how symptoms occur and interact in MS that will be essential for future studies. ..
  2. A Controlled Trial of CBT for MS Inflammation
    David Mohr; Fiscal Year: 2005
    ..We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation. ..
  3. A Controlled Trial of CBT for Multiple Sclerosis Inflammation
    DAVID DAIKH; Fiscal Year: 2007
    ..We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation. ..
  4. A Controlled Trial of CBT for Multiple Sclerosis Inflammation
    David I Daikh; Fiscal Year: 2010
    ..We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation. ..
  5. A Combination Trial of Copaxone Plus Estriol in RRMS
    Rhonda Voskuhl; Fiscal Year: 2009
    ..oral treatment with estriol, the major estrogen of pregnancy, induces a decrease in relapses in relapsing remitting multiple sclerosis (RRMS) subjects when used in combination with injectable Copaxone...
  6. A Combination Trial of Copaxone Plus Estriol in RRMS
    Rhonda Voskuhl; Fiscal Year: 2009
    ..oral treatment with estriol, the major estrogen of pregnancy, induces a decrease in relapses in relapsing remitting multiple sclerosis (RRMS) subjects when used in combination with injectable Copaxone...
  7. The Role of Mast in a Model of Relapsing-Remitting Multiple Sclerosis
    BLAYNE SAYED; Fiscal Year: 2007
    ..In this application, we will use an established model of relapsing-remitting multiple sclerosis to examine some of the potential mechanisms that underlie mast cell effects on a disease course. ..
  8. GENERAL CLINICAL RESEARCH CENTER
    Richard Rudick; Fiscal Year: 2006
    ..The GCRC, the centerpiece of our clinical research expansion, is critical to our goal of excellence in clinical research. ..
  9. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  10. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  11. Pregnancy and the Modulation of Multiple Sclerosis
    Annette Langer Gould; Fiscal Year: 2006
    ..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
  12. Physical Activity and Quality of Life in Multiple Sclerosis
    Robert Motl; Fiscal Year: 2007
    ..Before encouraging participation in physical activity, additional research is required that supports the link between physical activity and QOL and identifies factors that account for this relationship. ..
  13. Using the Internet to Improve Patient's Self-Management of Chronic Illness
    Deborah Miller; Fiscal Year: 2006
    ..The utilization analysis will allow us to identify the incremental benefit of the comprehensive system compared to the secure system and to determine where there greatest savings in overall cost of care is gained. ..
  14. PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
    Lawrence Steinman; Fiscal Year: 1993
    ..These approaches using therapeutic peptides could lead to the rational design of drugs for autoimmune disease...
  15. IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES
    Lawrence Steinman; Fiscal Year: 2001
    ..Aim 5 is to assess the possibility of using DNA vaccination against TCR Vb for treatment of EAE. It is hoped that these studies will provide the basis for future clinical trials in MS patients. ..
  16. MOLECULAR AND CELLULAR IMMUNOBIOLOGY
    Lawrence Steinman; Fiscal Year: 2007
    ..abstract_text> ..
  17. Large Scale Images of Gene Transcription in MS and EAE
    Lawrence Steinman; Fiscal Year: 2004
    ..The discovery of the role of osteopontin, first identified in large scale profiles, exemplifies how this approach may help us to understand MS and to develop new therapies. ..
  18. PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
    Lawrence Steinman; Fiscal Year: 2003
    ..This work with APL may be applicable not only to MS, but to other autoimmune diseases including juvenile diabetes, rheumatoid arthritis, and inflammatory bowel disease. ..
  19. IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES
    Lawrence Steinman; Fiscal Year: 1993
    ....
  20. Activity, Gait, and Efficacy (AGE) in Older Women
    Edward McAuley; Fiscal Year: 2005
    ..Only when we can reliably identify such patterns of relationships will we be effectively able to prescribe and promote public health agendas and programs to maximize health, function, and well-being in all older adults. ..
  21. Fish oil & alpha lipoic acid in mild Alzheimer's disease
    Lynne Shinto; Fiscal Year: 2004
    ..Compliance of fish oil supplementation will be assessed by red blood cell membrane fatty acid analysis. ..
  22. JCV Virus Expression in Oropharynx and HIV
    Joseph Berger; Fiscal Year: 2004
    ..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
  23. Antigen Identification in Chronic Inflammatory CNS Disease
    Mark Burgoon; Fiscal Year: 2007
    ..Determining the cause of these devastating neurologic diseases will have profound implications not only for early diagnosis but also for prevention of disease. ..
  24. NEUROSCIENCE OF HIV CONFERENCE
    Joseph Berger; Fiscal Year: 2002
    ..Dr. Brian Wigdahl, international co-chair of the ISNV, is a co-investigator on this grant. ..
  25. FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION
    JACK SIPE; Fiscal Year: 2006
    ..abstract_text> ..